As disclosed in a Schedule 13G filing with the U.S. Securities and Exchange Commission, Kevin Kotler’s Broadfin Capital holds an ownership stake of 1.66 million shares in Advaxis Inc. (NASDAQ:ADXS), accounting for 5.27% of the company’s outstanding common stock. This is up by 849,320 shares since the fund disclosed all of its public equity positions in its most-recent 13F filing submitted a few months ago.
Broadfin Capital is a global equity healthcare-focused hedge fund established by Kevin Kotler in June 2005. The New York-based firm aims to generate attractive long-term compounding returns by employing a value-oriented investment strategy that is based on proprietary fundamental research. Kevin Kotler, the experienced investor in medical technology companies, with more than 20 years of experience, intends to build his hedge fund into a leading investor in healthcare companies. Broadfin Capital’s stock picking approach focuses on finding companies that develop products designed to improve healthcare outcomes and lower costs. At the same time, the investment firm has both the necessary skills and capital to invest across all market capitalizations, ranging from small-cap to large-cap companies. As revealed by the fund’s most recent 13F filing with the SEC, Broadfin Capital manages a public equity portfolio with a market value of $1.28 billion as of March 31, 2015.
Follow Kevin Kotler's Broadfin Capital
Let’s first take a step back and analyze how tracking hedge funds can help an everyday investor. Through our research we discovered that a portfolio of the 15 most popular small-cap picks of hedge funds beat the S&P 500 Total Return Index by nearly a percentage point per month on average between 1999 and 2012. On the other hand the most popular large-cap picks of hedge funds underperformed the same index by seven basis points per month during the same period. This is likely a surprise to many investors, who think of small-caps as risky, unpredictable stocks and put more faith (and money) in large-cap stocks. In forward tests since August 2012 these top small-cap stocks beat the market by an impressive 65 percentage points, returning over 123% (read the details here). Follow the smart money into only their best investment ideas all while avoiding their high fees.
Advaxis Inc. (NASDAQ:ADXS) is a clinical-stage biotechnology company that is currently developing several cancer immunotherapies based on its proprietary Lm Technology. The company’s lead Lm Technology immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is currently in clinical trials for three indicators. We’ll discuss Advaxis’ lead product in more detail later on in this article. Meanwhile, the shares of Advaxis have gained nearly 107% year-to-date despite riding a steady downtrend since the beginning of June (read more details).
